Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Surged Today

By Joe Tenebruso - Apr 21, 2021 at 3:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced positive data for the coronavirus vaccine candidate it hopes to bring to the U.S. market.

What happened

Shares of Ocugen (OCGN 7.44%) climbed on Wednesday after the biopharmaceutical company's partner, Bharat Biotech, released promising results from a phase 3 trial of its COVID-19 vaccine candidate, Covaxin. 

As of 3 p.m. EDT, Ocugen's stock price was up more than 12% after rising as much as 22.5% earlier in the day.

So what 

A second interim analysis of a phase 3 study with 25,800 participants showed Covaxin to have efficacy against mild, moderate, and severe COVID-19 of 78%. Against severe COVID-19 alone, that figure came in at 100%.

"We believe that Covaxin can help change the course of this pandemic by preventing severe COVID-19 disease including hospitalizations by 100% as well as significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date," Ocugen CEO Dr. Shankar Musunuri said in a press release.

A person is pointing to a digital stock chart that rises, then falls, then rises again.

Investors bid up Ocugen's stock price on Wednesday. Image source: Getty Images.

Ocugen reached an agreement with India-based vaccine developer Bharat Biotech in February to commercialize Covaxin in the U.S., should it receive regulatory authorization. The deal gives Ocugen a 45% share of any potential profits, with Bharat Biotech receiving the remaining share. 

"We are dedicated to being a part of the solution to save lives from COVID-19 by bringing Covaxin to the U.S. market," Musunuri said.

Now what

Covaxin's efficacy is notable considering that multiple coronavirus variants were circulating at the time of the trial. Still, it remains to be seen whether there will be enough demand for the vaccine in the U.S., even if it receives Emergency Use Authorization.

Pfizer's and Moderna's vaccines have demonstrated efficacy of roughly 95%, though it's not an apples-to-apples comparison, since their clinical trials were conducted when coronavirus mutations were less prevalent. Still, Ocugen may find it challenging to wrestle away market share from these vaccine leaders in the U.S.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.60 (7.44%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.